Bristol Myers Squibb (CELG-RI) Equity Income (2010 - 2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Equity Income of $36.0 million for Q1 2013, down 70.49% year-over-year from $122.0 million in Q1 2012, and down 68.97% quarter-over-quarter from $116.0 million in Q3 2012.
Bristol Myers Squibb (CELG-RI) Equity Income (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Equity Income for 4 consecutive years, with $36.0 million the latest figure, recorded in Q1 2013.
- In Q1 2013, Equity Income fell 70.49% year-over-year to $36.0 million; the TTM figure through Mar 2013 stood at $394.0 million (down 26.36% YoY), while the FY2010 annual figure was $659.0 million, down 41.47% from the prior year.
- Equity Income retreated to $36.0 million in Q1 2013 per CELG-RI's latest filing, from $116.0 million in the prior quarter.
- Across five years, Equity Income topped out at $194.0 million in Q1 2010 and bottomed at $36.0 million in Q1 2013.
- Historically, Equity Income has averaged $133.3 million across 4 years, with a median of $131.0 million in 2010.
- Annual changes were most pronounced in 2011 — Equity Income dropped 7.09% — and 2013, when it tumbled 70.49%.
- Bristol Myers Squibb's Equity Income stood at $131.0 million in 2010, then changed by 0.0% to $131.0 million in 2011, then dropped by 11.45% to $116.0 million in 2012, then sank by 68.97% to $36.0 million in 2013.
- Business Quant data shows CELG-RI's Equity Income at $36.0 million in Q1 2013, $116.0 million in Q3 2012, and $120.0 million in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -10.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.03 Mn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 36.00 Mn |
| Sep 30, 2012 | 116.00 Mn |
| Jun 30, 2012 | 120.00 Mn |
| Mar 31, 2012 | 122.00 Mn |
| Sep 30, 2011 | 131.00 Mn |
| Jun 30, 2011 | 142.00 Mn |
| Mar 31, 2011 | 140.00 Mn |
| Dec 31, 2010 | 131.00 Mn |
| Sep 30, 2010 | 141.00 Mn |
| Jun 30, 2010 | 193.00 Mn |
| Mar 31, 2010 | 194.00 Mn |